Phaseline

Targets › ATR

ATR (Serine/threonine-protein kinase ATR): drug programs, companies and trials

8 programs from 5 companies in 48 trials: 26 Phase 1, 20 Phase 2, 2 Phase 3; Oncology; next expected readout Dec 2026.

Serine/threonine protein kinase which activates checkpoint signaling upon genotoxic stresses such as ionizing radiation (IR), ultraviolet light (UV), or DNA replication stalling, thereby acting as a DNA damage sensor. Recognizes the substrate consensus sequence [ST]-Q. Phosphorylates BRCA1, CHEK1, MCM2, RAD17, RBBP8, RPA2, SMC1 and p53/TP53, which collectively inhibit DNA replication and mitosis and promote DNA…. (UniProt, Q13535)

Open in Phaseline: the race on ATR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AstraZenecaceralasertib
Serine-protein kinase ATR inhibitor
ATRPhase 3Advanced or Metastatic Non-Small Cell Lung Cancer; Metastatic Triple Negative Breast Cancer; Melanoma; Non-Small Cell Lung Cancer …Dec 2026
National Cancer Institute (NCI)Tuvusertib
ATR kinase inhibitor
ATRPhase 2Castration-Resistant Prostate Carcinoma; Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8; Advanced Malignant Solid Neoplasm; Recurrent Endometrial CarcinomaJan 2027
National Cancer Institute (NCI)Berzosertib
ATR kinase inhibitor
ATRPhase 2Castration-Resistant Prostate Carcinoma; Extensive Stage Lung Small Cell Carcinoma; Ovarian Serous Tumor; Bilateral Breast Carcinoma …Feb 2027
National Cancer Institute (NCI)Elimusertib
Serine-protein kinase ATR inhibitor
ATRPhase 1Recurrent Alveolar Rhabdomyosarcoma; Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Metastatic Lung Small Cell Carcinoma; Advanced Fallopian Tube Carcinoma …Jan 2027
M.D. Anderson Cancer CenterBerzosertib (M6620)
ATR (ataxia telangiectasia and Rad3-related protein) kinase inhibitor
ATRPhase 1Metastatic Malignant Solid NeoplasmJan 2027
Debiopharm InternationalRP-3500
ATR inhibitor
ATRPhase 1Advanced Solid Tumor; Solid TumorDec 2027
National Cancer Institute (NCI)Camonsertib
ATR inhibitor
ATRPhase 1Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8May 2029
Acerta PharmaCeralasertib (AZD6738)
Serine-protein kinase ATR inhibitor
ATRPhase 1Chronic Lymphocytic Leukemia–

Conditions

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 (2) Advanced Breast Carcinoma (2) Extensive Stage Lung Small Cell Carcinoma (2) Castration-Resistant Prostate Carcinoma (2) Advanced Malignant Solid Neoplasm (2) Recurrent Alveolar Rhabdomyosarcoma (1) Metastatic Lung Small Cell Carcinoma (1) Advanced Fallopian Tube Carcinoma (1) Advanced Bile Duct Carcinoma (1) Advanced Colorectal Carcinoma (1) Advanced or Metastatic Non-Small Cell Lung Cancer (1) Metastatic Triple Negative Breast Cancer (1)

Modalities

small molecule (4), mixed (3), protein or peptide (1)

Companies

National Cancer Institute (NCI) (4) AstraZeneca (1) M.D. Anderson Cancer Center (1) Debiopharm International (1) Acerta Pharma (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.